Ozempic for Weight Loss: Clinical Eligibility & Access Pathways

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Accessing Ozempic for weight loss requires a clinical evaluation confirming medical eligibility, typically a BMI of 30 or higher or 27+ with obesity-related conditions. Unlike over-the-counter supplements, GLP-1 receptor agonists are prescription medications requiring provider oversight to ensure safety and efficacy.

Weight loss medication decisions are most effective when paired with a comprehensive health assessment. PlexusDx supports precision wellness by helping providers understand individual genetic predispositions in peptide pathways, enabling more informed discussions about formulation type, dosing strategy, and long-term sustainability.

Understanding Medical Eligibility Criteria

Ozempic prescriptions for weight loss require documented medical eligibility. The FDA approves semaglutide for chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidities like type 2 diabetes, hypertension, or cardiovascular disease. A qualified provider must evaluate your complete health history.

Providers assess contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe gastrointestinal disease. Pregnancy status, medication interactions, and kidney or liver function are also reviewed. This evaluation ensures the medication aligns with your individual safety profile.

Key Clinical Markers That Guide Treatment Decisions

Beyond BMI, providers evaluate baseline metabolic markers to personalize GLP-1 therapy. Fasting glucose, HbA1c, lipid panel, and inflammatory markers help determine baseline metabolic health and predict treatment response patterns. Genetic factors in peptide signaling pathways also influence individual variation in efficacy and tolerability.

Clinical Factor	Why It Matters for GLP-1 Treatment
BMI / Weight Status	Determines medical eligibility and baseline treatment intensity; higher BMI often correlates with greater metabolic dysfunction.
Fasting Glucose / HbA1c	Indicates existing insulin resistance; GLP-1s improve glucose control independent of weight loss in many patients.
Lipid Panel (LDL, HDL, Triglycerides)	Baseline lipid abnormalities often improve with GLP-1 therapy; baseline assessment guides expectation-setting.
Gastrointestinal History	Pre-existing GERD, gastroparesis, or pancreatitis require careful evaluation; GLP-1s slow gastric emptying and may worsen symptoms in susceptible individuals.
Genetic Peptide Pathway Variants	Predispositions in GLP1R, GIPR, FTO, and MC4R genes may influence individual response magnitude and tolerability profile.

Choosing Between Branded and Compounded GLP-1 Options

Patients often encounter both branded GLP-1s (Ozempic, Wegovy, Mounjaro) and compounded alternatives. Branded medications undergo FDA approval and manufacturing standardization. Compounded versions from licensed 503A pharmacies are prepared by state-licensed pharmacists under sterile conditions and may offer cost savings and flexibility in dosing schedules.

The choice depends on insurance coverage, availability, cost tolerance, and provider preference. PlexusDx offers compounded semaglutide and tirzepatide formulations at lower monthly costs ($149/mo), with customizable dosing protocols. A qualified provider helps determine whether branded or compounded formulation best fits your clinical needs and financial situation.

Provider Consultation: What to Expect and How to Prepare

Starting GLP-1 therapy begins with a thorough provider consultation via telemedicine or in-person visit. Bring recent labs (lipid panel, fasting glucose, liver and kidney function), current medications, and a detailed health history including gastrointestinal symptoms, family history of thyroid cancer, and prior weight loss attempts. This documentation enables informed prescribing decisions.

During consultation, discuss your weight loss goals, lifestyle factors (diet, exercise, sleep), and tolerance for potential side effects. The provider reviews mechanism of action, realistic expectation timelines (weight loss typically begins 2–4 weeks into treatment), and monitoring protocols. Ask about long-term sustainability plans; GLP-1s are chronic maintenance therapies, not short-term interventions.

Safety Considerations and Who Should Not Use GLP-1 Therapy

Certain individuals should not use GLP-1 medications. Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and severe allergic reaction to semaglutide. Pregnancy and breastfeeding are contraindications; women of childbearing age should use effective contraception during treatment.

Common side effects include nausea, vomiting, constipation, and reduced appetite—usually mild and transient. However, serious adverse effects are rare but possible: pancreatitis, severe dehydration, and gallbladder complications. Patients with active or recent pancreatitis, severe kidney disease, or unstable cardiovascular disease require careful evaluation. Ongoing provider monitoring ensures safety throughout treatment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about individual predispositions in GLP1R, GIPR, FTO, and MC4R genetic variants, which can influence peptide pathway responsiveness. Understanding these genetic markers supports a more informed conversation with your provider about whether GLP-1 therapy aligns with your individual biology. The test costs $99 as an add-on or $298 standalone.

The Precision Peptide Genetic Test reveals predispositions in peptide signaling pathways but does not predict exact medication response or guarantee outcomes. Genetic predispositions are one factor among many—lifestyle, comorbidities, baseline metabolic health, and medication adherence also shape treatment results. These insights should be interpreted with a qualified healthcare provider.

When discussing GLP-1 options with your provider, sharing genetic predisposition data can support more personalized treatment planning. If you're considering compounded semaglutide, tirzepatide, or PlexusDx's dual-compound GLP-Squared protocol, genetic context may inform whether microdose protocols or standard dosing schedules align best with your peptide pathway biology. Always ensure your provider reviews all clinical and genetic information before treatment initiation.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.